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Coronary Artery Disease: Improved Ventricular Wall Motion,
Increased Pump Function and Abolition of Pacing-Induced Ischemia
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MARTIN GOTTWIK, MD, MANFRED KINDLER, PhD
Bad Nauheim, West Germany
AR-L 115 BS (Sulmazol) is a new noncatechol, nongly-
cosidic cardiotonic agent. In 17 patients with significant
coronary artery disease, the influence of AR-L 115 BS
on hemodynamics and regional wall motion was inves-
tigated under the following conditions: 1) control, 2) the
immediate postpacing period without medication, and
3) the postpacing period under the peak influence of AR-
L 115 BS, 2 mg/kg intravenously. During the postpacing
phase without medication, all patients developed isch-
emia (angina, ST segment alterations, increase of mean
left ventricular end-diastolic pressure from 13 to 30 mm
Hg), left ventricular pump function diminishedand overaU
regional wall motion showed a tendency to decrease (p
> 0.05). However, during the postpacing period with
AR-L 115 BS medication, ischemia was abolished (no
Recent experimental and clinical data (1-5) have revealed
the action of AR-L 115 BS (Sulmazol = 2-[2-methoxy-
4 methyl-sulfinyl-phenyl] imidazo [4,5-b]pyridine) to be
similar to that of arnrinone (6 ,7) although there is no struc-
tural relation. In general, the drug exhibits positive inotropic
effects and causes reduction of preload and afterload, thus
meeting the requirements for the treatment of congestive
heart failure. With respect to its positive inotropic action,
the drug may be compared with the catecholamines (8).
Whereas catecholamines augment left ventricular function
and concomitantly lower anginal threshold by increasing
myocardial oxygen consumption, the newly developed drug ,
AR-L 115 BS, increases left ventricular pump function with-
out inducing angina in patients with documented coronary
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angina; mean left ventricular end-diastolic pressure de-
creased to 13 mm Hg; hemodynamic variables returned
to control levelsand left ventricular pump function showed
some improvement while overall regional wall motion
showed tendencies to improve. A comparison of alter-
ations of hemodynamics and regional wall motion during
the postpacing phase without medication with those un-
der the influence of AR-L 115 BS shows that overall left
ventricular pump function and regional wall motion im-
proved while angina and an increase in left ventricular
end-diastolic pressure were prevented.
It is concluded that AR-L 115 BS improves left ven-
tricular pump function and regional wall motion in coro-
nary artery disease without inducing ischemia, probably
by means of a reduction in extravascular resistance.
artery disease, while the concomitant increase in myocardial
oxygen consumption is found not to be inappropriately high
(5) . Elevated left ventricular end-diastolic pressure is a dis-
tinct feature of the vicious cycle in hemodynamic alterations
that result in the clinical state of angina.
The aim of this study was to investigate whether, despite
an increase in left ventricular work load, angina could be
prevented by reducing left ventricular end-diastolic pressure
in patients with a stable anginal threshold. Consequently,
it seemed of importance to study impaired left ventricular
regional wall motion at a time when angina-inducing mea-
sures were applied under the effects of the positive inotropic
substance, AR-L 115 BS. The present study focusing on
AR-L lIS BS-induced changes in regional wall motion in
patients with coronary artery disease is a consequence of
our initial investigations (4,5) , which established the ben-
eficial hemodynamic effects of intravenous and oral admin-
istration of the drug in patients with primary cardiomyopathy
with greatly reduced ejection fraction , and outlined the met-
abolic costs of its action in ischemic heart disease.
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Table 1. Clinical Characteristics of the Study Group
, Mean value z: standard deviation
ECG = electrocardiogram; LV = left ventncular: NYHA New
York Heart Association: ( + ) = present
Methods
Patients. Investigations were performed in 17 men (mean
age range 53 to 62 years) during routine cardiac catheter-
ization for evaluation of coronary artery disease. In these
patients, stable angina and a positive exercise electrocar-
diogram accompanied by an increase in pulmonary artery
pressure without cardiac enlargement on X-ray examination
were indications for cardiac catheterization. Duringthe pro-
cedure, patients were chosen for extended investigation when
ischemia with anginal pam, augmentation of left ventricular
end-diastolic pressureand typical electrocardiographic changes
could be provoked by ventricular pacing. Detailed clinical
and hemodynamic values characterizing the study group are
listed in Table I.
Procedure. Written informed consent was obtained from
all patients before diagnostic cardiac catheterization, and
theadditional hemodynamic investigations during AR-L 115
BS treatment were carried out. Radiation exposure to the
total body and critical organs did not exceed the usual dos-
ages known to occur for such routine. Before study, no
medication was administered and nitrates and beta-adren-
ergic blockingagents, the only cardioactive drugs used reg-
ularly by all patients, had been withheld for at least three
drug half-lives. All patients were studied during normal
sinus rhythm.
Left heart catheterization was performed by the retro-
grade technique. After measurement of left ventricular sys-
tolic and end-diastolic pressure, biplane angiography was
performed in the 30° right anterior oblique projection with
injection of 40 ml of Urografin-7 . Thereafter, coronary ar-
teriography was carried out using the Judkins technique. At
least 20 minutes was allowed for adequate dissipation of
the last injection of contrast mediumto assurecorrecthemo-
No of patients
Age (yr)
NYHA functional class
Sinus rate (be ats /rmn )
LV systolic pressure (mm Hg)
LV end-d ras tohc pressure (rnrn Hg)
Ejection fraction (% )
Cardiac index (liters/min per 1112)
Reproducible exertional angina
" Scars" of previous myocardial infarction
on ECG
Luminal coronary occlusion ( 2: 75%)
I Vessel disease
2 Vessel disease
3 Vessel disease
17
53 z: 6'
2 4 z: 0.4'
76 z: II'
us z: zs-
13 z: 5*
59 z: 14'
3 2l! z: 1 1*
(+ ) all 17 patients
10 (59 '*')
7 (4 1%)
7 (4Io/c)
3 ( 18,*,)
dynamic measurements (9). Right ventricular pacing was
then irntiated at a rate of 110 beats/min and was gradually
increased to a rate of 170 beats/min while left ventricular
pressure was monitored. The pacing rate was kept constant
for 60 to 90 seconds. If leftventricularend-diastolic pressure
was increased in the immediate postpacing period and typ-
ical ST segment alterations were noted in the electrocar-
diogram, the patients were subjected to an extended inves-
tigation . After a pause of 20 minutes, pacing was again
initiated and a second ventriculogram was obtained im-
mediately after pacing was stopped. Identical pacing stress
and postpacing ventriculography were repeated 14 minutes
after the administration of AR-L 115 BS, 2 mg/kg body
weight intravenously. According to our earlier study (4),
the peak action of this drug occurs within 10to 15 minutes.
Twelve lead electrocardiograms were carried out before and
immediately after each pacing period, before leaving the
catheterization laboratory. I hour later and 24 hours later.
Measurements. Quantitation of regional wall motion was
achieved by a computer-assisted method (10, II) . The ven-
tricular silhouette in diastole and systole was projected on
a graphic tablet (Tektronix) and digitized by tracing the
contour after introduction of the appropriate calibration fac-
tor. Conventional variables of volume and function were
calculated by the area-length method (12). For the purpose
of this study, regional wall motion was determined with
biplane ventriculography using right and left anterior oblique
positions. The computer-assisted procedure was based on a
radial model, in which the two silhouettes are rotated around
their superimposed centers of gravity and orientated along
the connecting line between the center of gravity and the
center of the aortic root. Eightradials were used todetermine
the translocation of identical points of the ventricular sil-
houette from diastole to systole. The shortening of each
radial was expressed in percent by calculating fractional
reduction of surface area of eight segments: a posterobasal
segment (60°) = AI, a posterior segment (60°) = A2, an
apical segment (120°) = A3, an anterior segment (60°) =
A4 and an anterobasal segment (120°) = AS on the right
anterior oblique silhouettes; using the left anterior oblique
view. a septal segment (120°) = A6. an anterolateral seg-
ment (120°) = A7 and a posterolateral segment (120°) =
A8. From an average of 34 pairs of ventriculograms per
patient. the fractional reduction of the surface areas AI
through A8 ranged from 52 ± 9t073 ± 8.7%(10,11).
Hemodynamic indexes were calculated from pressure
andoutputdatawith use of standardformulas (/3) : systemic
vascular resistance (SVR) in dynes-s-cm- 5 = (AOMP-
RAM)/CO x 80; left ventricular stroke workindex(LVSWI)
in g-rn/m? = SVI x (AOMP-LVEDP) x 0.0136, where
AOMP = mean aortic pressure, RAM = right atrial mean
pressure, SVI = stroke index and LVEDP = leftventricular
end-diastolic pressure. Student's 1 test for paired and un-
paired data was used for statistical evaluation of the results.
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Results
heart rate by + 19%, aortic mean pressure by +6%, cardiac
index by + 24%, stroke index by + 17%, systemic vascular
resistance by - 6% (not significant), ejection fraction by
+ 25% and mean circumferential fiber shortening rate by
+36%.
Alterations in regional wall motion (Tables 2 and 3).
Comparison of the medicated postpacing phase (that is,
drug-abolished ischemia) versus postpacing phase without
medication (that is, pacing-induced ischemia) indicates that
regional wall motion generally improved with AR-L 11 5
BS. The majority of angiographic segments exhibited di-
minished fractional shortening in the postpacing phase with-
out medication, while even more segments exhibited im-
proved fractional shortening in the postpacing phase under
the influence of AR-L 115 BS. However, theresulting changes
in regional wall motion presented in this mannerneglect the
rather differing degree of coronary obstructive disease in
individual cases and the modifications of individual con-
tractile patterns. Only from an analysis of all areas does it
become apparent that 86 (63%) of 136 areas showed a re-
duction in fractional shortening during the postpacing phase
without medication while 18 of these segments showed a
smaller decrease or even improvement after AR-L 115 BS;
these may have been potentiallyischemicsegments. Further
analysis revealed that 50 (37%) of the 136 areas show an
increase in regional wall motion after pacing without the
drug. Of these areas, which may well have been normal,
33 showed a further small increase after medication, pre-
sumably because of the inotropic effect of AR-L l IS BS,
or did not increase regional wall motion as much as without
the drug, possibly because abnormal wall motion eleswhere
in the ventricle was less marked after AR-L 115 BS.
Side effects. Neither subjective nor objective clinically
adverse or toxic manifestations were observed during or
after the administration of AR-L 115 BS and during med-
icated stress conditions, except for transient visual distur-
bances regarding light-darkness visibility. The latter are known
to occur during the first seconds of intravenous infusion of
AR-L 115 BS from the experiences of our initial studies
with the drug (4,5). Twelve lead electrocardiograms re-
corded immediately after administration of AR-L 115 BS
and 60 minutes later showed no changes compared with
electrocardiograms obtained on admission and 24 hours after
completion of the study. At no time during and after the
study was there any indication of extrasystolic activity or
any other arrhythmias.
Discussion
In this and previous clinical studies (5, 14, 15), AR-L 115
BS elicited marked positive inotropic effects in regard to
left ventricular pump function. Accordingly, cardiac index,
stroke index, stroke work index and ejection fraction were
increased during treatment with this drug. Although low
10
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Figure 1. Left ventricular pump function in the 17 patients with
coronary artery disease decreased in the postpacing period (PPP)
with signs of myocardial ischemia, while in the postpacing phase
under the influence of AR-L 115 BS (2 mg/kg intravenously) (AR-
L) an increase in left ventricular stroke work index (LVSWI) of
73% was achieved. Simultaneously, left ventricular end-diastolic
pressure (LVEDP) decreased considerably (by 57%) and angina
was no longer present. Values are mean ± standard error of the
mean.
Hemodynamic alterations. Hemodynamic alterations
under stress conditions in the postpacing phase withoutmed-
icationand in the postpacingphase during the peak influence
of AR-L 115 BS are listed in Table 2. It is apparent that
variables of left ventricular function decreased in the post-
pacing phase. According to selection criteria, all patients
experienced reproducible exertional angina and exhibited
ST segment alterations with a concomitant increase in left
ventricular end-diastolic pressure. From the prepacing level
(at rest) of 13 ± 5 mm Hg, mean left ventricular end-dia-
stolic pressure increased to 30 ± 5 mm Hg during angina
in the postpacing phase, but remained in the prepacing range
(13 ± 4 mm Hg) in the medicated postpacing phase. Fur-
thermore, angina pectoris and ischemic ST segment changes
were abolished. In Figure I the mean changes in left ven-
tricular pump function are defined by the relation of left
ventricular stroke work index to left ventricular filling pres-
sure (left ventricular end-diastolic pressure) during rest and
in the postpacing phase with and without medication (AR-
L 115BS). Left ventricular pump function in the postpacing
phase without medication decreased by 35% and was ac-
companied by signs of myocardial ischemia, while in the
postpacing phase with medication at peak drug influence an
average increase in stroke workindex of + 75% was achieved;
simultaneously left ventricular end-diastolic pressure de-
creased considerably (by 57%) and angina was no longer
present.
The other variables comparing the postpacing phase with
and without medication changed significantly as follows:
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Heart rate (beats/min)
LV systolic pressure
(mm Hg)
LV end-diastolic pressure
(mm Hg)
Aortic mean pressure
(mrn Hg)
Cardiac index (hters/rnm
per m')
Stroke index (rnl/rrr')
LV stroke work index
(gm/rrr')
Systemic vascular resistance
(dynes-s-cm - 5)
End-diastolic volume index
(rnl/rrr')
Ejecnon fracnon (%)
Mean crrcurnferennal fiber
shortening rate (circ/s)
Re;t
76 ± II
138 ± 28
13 ± 5
94 ± 16
33 ± I I
46 ± 13
51 ± 19
l,311 ± 429
80 ± 15
59 ± 14
I II ± 043
PPP
73 ± 10
136 ± 28
30 ± 5
83 ± 12
34 ± 8
47 ± II
33 ± 10
1,034 ± 294
91 ± 14
52 ± 10
094 ± 0.3
PPP + ARL
87 ± 14~
130 ± 27
13 ± 4*
88 ± 10*
4.12 ± 1*
55 ± 15'
57 ± 18*
972 ± 375
85 ± 18
65 ± 14*
I 28 ± 0.44*
*Probabihty (p) < 005 versus value in postpacmg period (PPP).
LV = left ventricular; PPP = postpacing pcnod (without drug); PPP+ ARL = postpacmg phase under influence of AR-L 115 BS; Rest = control
condition; at rest.
doses of AR-L 115 BS (up to I mg/kg) in the experimental
preparation did not cause myocardial oxygen consumption
to increase significantly (3), our previous results (5) reflected
an increase in myocardial oxygen consumption appropriate
to metabolic demands, It is safe to assume, therefore, that
in the present study myocardial oxygen consumption might
have been augmented considerably by the added effects of
ventricular pacing.
Effects on myocardial ischemia. In spite of these ef-
fects, administration of AR-L 115 BS abolished ischemia
during pacing stress. Such raising of the anginal threshold
was not caused by a mere decrease in systemic vascular
Table 3. Alterations in Regional Wall Motion (%)
Regional Areas
(angiography) Re;t PPP PPP+ARL
Right anterior oblique view
Posterobasal (A I ) 31 ± II 26 ± 14 36 ± 15
Posterior (A2) 35 ± 22 38 ± 22 48 ± 21
Apical (A3) 35 ± 6 30 ± II 38 ± 13
Anterior (A4) 36 ± 19 45 ± 19 51 ± 20
Anterobasal (A5) 44 ± 12 38 ± 19 55 ± 15
Left antenor oblique view
Septal (A6) 40 ± 9 33 ± 10 40 ± 15
Anterolateral (A7) 37 ± 13 35 ± II 41 ± 15
Posterolateral (A8) 39 ± 10 33 ± 12 41 ± 13
Significant differences (p < 0.05, at least): I) all values PPP vs rest
(except for A6), 2) all value; (PPP + ARL) vs PPP (except for A4 and
A7)
Abbreviations a; tn Table 2
resistance because there was no statistically significant dif-
ference between the degree of decreased stroke index in the
pacing periods with and without AR-L 115 BS. Rather, the
decrease of left ventricular end-diastolic pressure appears
to have been responsible. There is proof (also for the clinical
setting) that because of elevation of extracoronary resis-
tance, the tachycardia itself impairs coronary flow inversely
in relation to heart rate (16). Hence, a decrease in perfusion
pressure during tachycardia, as judged by changes in mean
aortic pressure, plays only a minor role in this setting. In
patients with significant narrowing of the lumen of the coro-
nary artery, the determining factor for tissue perfusion is
the poststenotic perfusion pressure, primarily affecting the
subendocardial layers, When the poststenotic perfusion
pressure diminishes during and after pacing while ischemia
simultaneously leads to an increase in left ventricular end-
diastolic pressure, the perfusion pressure gradient is greatly
diminished, By lowering or preventing an increase in left
ventricular end-diastolic pressure, impairment of subendo-
cardial perfusion is counteracted. Thus, even an increased
demand of oxygen does not lead to utilization of coronary
reserve beyond its limits, It is as yet unclear if and to what
degree treatment of latent congestive failure alone decreases
left ventricular end-diastolic pressure and to a lesser extent
end-diastolic volume, Also unknown is how much is due
to reduction of preload by venous pooling.
Effects on regional wall motion. It is not surprising
that the overall effects of the drug on regional wall motion
are not as striking (although average alterations during the
medicated postpacing phase versus the postpacing phase
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without medication are significant in six of eight areas)
because coronary artery involvement varies within a wide
spectrum. However, in all patient s , improvement of regional
wall motion was seen after pacing with administration of
AR-L 115 BS, provided impairment during pacing without
medication was detected with optimal accurac y with the
method applied. In a number of patients, it became obvious
that regional wall motion , already showing impairment at
rest , improved markedl y under the influence of AR-L 11 5
BS. Thu s, the question arises whether these ischemic areas
might be amenable to bypass surgery.
Effects in cardiomyopathy with congestive failure. It
is of interest that in a recent study (4) AR-L 115 BS exhibited
beneficial hemodynamic effect s in patient s with congestive
cardiomyopathy with New York Heart Association func-
tional class Ill /IV symptoms (and a reduced ejection fraction
of 31.4 ± 0 .7%). In these II patient s whose condition was
inadequ ately controlled even with full conventional treat-
ment including digitalis , the administration of AR-L 115
BS, 3 mg/kg intravenously, induced a mean increase in
cardiac output of 2 1% and a decrease in pulmonary artery
pressure of 25%. In addition , oral administration of AR-L
115 BS, 200 mg every 8 hours, over a 4 day period in 18
patients with congestive cardiomyopathy (cardiac index 2.03
± 0 .24 liters/min per rrr'; ejection fraction 33 ± 6%) re-
sulted in a 31% increase in cardi ac index and a 35% increase
in ejection fraction. Thu s, residual contractile reserve was
mobilized in the fully digitalized heart in patients with pri-
mary cardiomyopathy and reduced ejection fraction, by both
intravenous and oral admini stration of AR-L 115 BS.
The beneficial therapeutic potent ial of this drug in
conges tive cardiomyopathy, achieved without serious side
effects, led to the question of its applicability in obstructive
coronary artery disease. Would AR-L 115 BS exhibit its
positive hemodynamic effects without inducing or aggra-
vating ischemia? Therefore , we set out to first establish the
metabolic costs of its action in ischemic heart disease (5),
and only thereafter did we study hemodynamics in associ-
ation with the analysis of alterati ons in regional wall motion.
Thu s, our present results are encouraging for the use of the
drug in coronary artery disease as well as in congestive
cardiomyopathy .
Side effects. Obviously, the careful study of the side
effects of AR-L 115 BS will be crucial to further clinical
evaluation and future use of this drug . As reported in our
initial studies (4, 5), the only adverse clinical manifestation
encountered related to transient visual disturbances regard-
ing light-darkness visibility. During the intravenous injec-
tion of AR-L 115 BS, in doses of 3 mg/kg (4) and 2 mg/
kg (5), patients experien ced a transient " dimming effect"
of the light in the room over a period of seconds or minutes .
To further investigate this phenomenon we arranged for
studies in collaboration with the Max Planck Institute for
Physiological and Clinical Research , Bad Nauheim, West
Germany, and with the Ophthalmological Clinic of the Uni-
versity of Frankfurt , West Germany (17, 18) . These studies
revealed that the drug caused an increase in amplitude of
the visual-evoked cortical potential in respon se to contrast
stimulation, which correlated with an increa se in visual acu-
ity. Apparently, high doses of AR-L 115 BS had a specific
effect on the visual system, causing rever sible color vision
deficiencies, which strongly correlated with the drug's serum
level.
In longer-term studie s, EI Allaf and Carlier at the Uni-
versity Clinic of Liege, Belgium, are involved in a study
of chronic use of AR-L 115 BS in patients in New York
Heart Association functional class Ill /IV with coronary ar-
tery disease and primary cardiomyopathy. With an oral de-
pot preparation of the drug, applied every 8 hours over
approximately 1 year, they have seen beneficial hemody-
namic effect on left ventricular pump function without ad-
verse clinical side effect s (personal communication).
Implications. In spite of abundant experimental work ,
the exac t mode of action of AR-L 115 BS is still unkno wn.
Phosphodiesterase inhibition and calcium influx alterations
are involved, but to what extent and by what mechanism
remain to be investigated. Although the findings presented
here cannot add to the solution, they aid in the understanding
of the mechanism of angina pectori s. In addition , the prop-
erties of AR-L 115 BS demon strated in this study support
the notion that the drug might be useful in improving left
ventricular pump function in patients with obstructive coro-
nary artery disease without inducing or augmenting myo-
cardia l ischem ia.
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